Developer docs
API playgroundTry for free, no card

Search company profiles

Chemify

Full company profile

uuid0000aeo

Namestring
Chemify
Legal namestring
Chemify Limited
Websiteurl
chemify.io
Company typeenum
Private
Founded yearint
2022
Descriptiontext

Chemify is a privately held digital chemistry company founded in 2022 as a spin-out from the University of Glasgow, headquartered in Glasgow with an operational footprint extending to the United States (planned Silicon Valley hub) and Japan (via Zeon partnership). The company operates the Chemputation platform, which integrates a generative AI design engine (Quantum Chemputation), an ML-based route optimization tool (ASSEMBLER), and a proprietary universal chemical programming language (χDL) with advanced robotic synthesis infrastructure housed in the Maryhill Chemifarm facility opened in 2025. Together these components execute closed-loop Design-Make-Test-Analyze cycles that translate target molecules into executable, hardware-agnostic chemical code, with the platform reporting a 10x reduction in time from conception to compound synthesis.

Chemify generates revenue primarily through bespoke, multi-year R&D and custom-synthesis collaborations with pharmaceutical, biotechnology, advanced-materials and global-health counterparties, complemented by success-based clinical and regulatory milestones and tiered royalties on compounds the platform designs. Pricing is quote-based and negotiated per program, with disclosed deal economics such as USD $30M+ in payments plus single-digit royalties per molecule in the Prepaire Labs opioid program. Its go-to-market is enterprise sales-led (CBO and SVP Business Development) supplemented by industry conferences, scientific thought leadership, and PR-driven awareness. The company has raised over $90M across a $43M Series A (Aug 2023) and an oversubscribed $50M+ Series B (Oct 2025), with a strategic investment from Zeon Ventures in February 2026 and grant funding from the Bill & Melinda Gates Foundation totaling approximately £2.4M for tuberculosis and malaria drug discovery.

Short descriptiontext

Chemify is a Glasgow-based digital chemistry company that uses its Chemputation platform — combining generative AI design, ML-based route optimization, the proprietary χDL chemical programming language, and automated robotic synthesis — to design and produce small molecules for pharma, biotech, advanced-materials, and global-health partners under bespoke R&D and milestone/royalty agreements.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersGlasgow, United Kingdom
HQ citystring
Glasgow
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
digital chemistry platform, automated drug discovery, chemical programming language, robotic synthesis services, AI molecular design
Industry2 codes
PRIMARYHLAGAJAE
Cheminformatics & Molecular Modeling / CADD
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing32541
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Medicinal Chemicals & Botanical Products2833
Product category
Digital Chemistry Platform
Social media profiles1 record
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model3 records
1Bespoke R&D Partnerships / Custom Synthesis
TypeProfessional Services
Description

Project-based collaborations with pharmaceutical, biotechnology, and materials companies in which Chemify designs, discovers, and synthesises bespoke molecules using the Chemputation platform. Engagements span multiple years and milestones, often including a defined number of design–make cycles or compounds delivered.

chemify.io
2Success-Based Milestones and Royalties
TypeLicensing Royalties
Description

Multi-year milestone and royalty structures tied to clinical and regulatory progress of compounds Chemify designs for partners. For example, the Prepaire Labs opioid program includes at least USD $30 million in payments and pre-negotiated clinical/regulatory milestones per developed molecule, plus single-digit royalties on resulting products. Similar tiered royalty structures apply to Dewpoint Therapeutics.

chemify.io
3Option-to-Acquire Compound Rights
TypeLicensing Royalties
Description

For certain partnerships (e.g., Dewpoint), the partner may exercise an option to acquire compounds designed by Chemify; in exchange Chemify receives pre-negotiated, success-driven payments and tiered royalties based on clinical and regulatory milestones.

chemify.io
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales, Supply Chain
Pricing details1 tier
1Quote-based bespoke partnership engagements initiated via the 'Partner With Us' form.
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing not publicly disclosed; terms negotiated per program and typically include upfront R&D payments, success-based clinical/regulatory milestones, and royalties on any resulting products.

chemify.io
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 4 records shown
1Chemifarm
Description

Chemify's branded fully automated synthesis facility (Chemputation facility); the first Chemifarm opened in Maryhill, Glasgow in 2025.

chemify.io
+3 more records
Core offering1 text field

Chemify provides an integrated digital chemistry platform, called Chemputation, that combines ML-based molecular design (Quantum Chemputation), ML-driven route optimization (ASSEMBLER), and a proprietary universal chemical programming language (χDL) executed by advanced robotic synthesis systems. Through its Chemifarm automated synthesis facility in Glasgow, the company delivers fully automated Design–Make–Test–Analyze cycles to pharmaceutical, biotechnology, advanced materials, and global health customers under bespoke R&D partnerships and milestone/royalty-bearing collaboration agreements. Chemify also offers standalone capabilities including upfront Chemputability makeability assessment and massive library derivatization deep into chemical space.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 10x reduction in time from initial conception to compound synthesis via Chemputation platform
+2 more records
Product overview1 text field

Chemify offers a single unified platform called "Chemputation" that combines three interlocking technology modules — Quantum Chemputation (generative AI-driven molecular design), ASSEMBLER (ML-based route optimization using the proprietary reaction database), and χDL (the world's first universal chemical programming language) — executed by Chemify's advanced robotics infrastructure within the Chemifarm automated synthesis facility in Maryhill, Glasgow. The platform is delivered to partners as a digital-to-physical discovery service spanning custom synthesis, scale-up for preclinical testing, Chemputability makeability scoring, and massive library derivatization deep into chemical space. Together these modules enable fully automated Design-Make-Test-Analyze cycles that translate target molecules into executable chemical code run on robotic systems.

Product and service3 records
1Chemputation Technology Platform
CategoryCore platform
Description

Integrated digital chemistry platform combining Quantum Chemputation (ML-based generative molecular design), ASSEMBLER (route optimization), and χDL (universal chemical programming language), executed by advanced robotic systems to deliver fully automated Design-Make-Test-Analyze cycles for pharmaceutical, biotechnology, materials, and global health partners.

2Chemputability Makeability Assessment
CategoryMakeability assessment service
Description

Algorithmically scores each molecule's Chemputability (practical makeability) before synthesis by comparing reaction steps against Chemify's database of tens of thousands of validated, optimized, and automated reactions; suggests Chemputable alternative structures when designs are not readily synthesizable.

3Massive Library Derivatization
CategoryDiscovery service
Description

Generates large derivatized libraries from established synthetic routes encoded in χDL, incorporating physicochemical parameters, druglike parameters, and makeability considerations; enables deep chemical-space exploration and gram-scale automated synthesis from a key advanced intermediate.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1Sanacor
Strategic tierFlagship Co-Development Partner For Cardiometabolic PipelineTypeStrategic or Co-development PartnerAnnounced on2026-02-25
Description

Collaboration announced February 2026 to discover and develop orally available small-molecule inhibitors targeting mitochondrial dysfunction in cardiometabolic diseases, with initial focus on diabetic cardiovascular disease. Combines Chemify's ML-based Chemputation platform for molecular design and automated synthesis with Sanacor's translational biology platform led by CEO and Co-founder Dr. Michael Widlansky.

pharmiweb.com
Strategic tierFlagship Strategic Partner For Opioid ProgramsTypeStrategic or Co-development PartnerAnnounced on2024-01-18
Description

Expanded partnership announced January 2024 with the 'Toxifree' program to develop a novel class of digitally discovered non-addictive opioids and addiction treatments in response to FDA's CDER guidance on stimulant use disorder. Combines Chemify's Chemputation platform with Prepaire's open-architecture drug discovery platform. Chemify entitled to at least USD $30 million in payments and pre-negotiated clinical/regulatory milestones per developed molecule, plus single-digit royalties.

Strategic tierFlagship Strategic Partner For Oncology And NeurodegenerationTypeStrategic or Co-development PartnerAnnounced on2023-09-12
Description

Partnership announced September 2023 to design, discover, and automatically synthesize novel molecules against condensate targets in Dewpoint's oncology and neurodegeneration pipeline. Combines Chemify's chemistry AI and automation platform with Dewpoint's condensate biology platform. Chemify receives pre-negotiated success-driven payments and tiered royalties; Dewpoint may exercise an option to acquire compounds.

Strategic tierCore Co-Development Partner For Tb ProgramTypeStrategic or Co-development Partner
Description

Collaborating with Chemify on the Bill & Melinda Gates Foundation–funded tuberculosis drug discovery program. Lgenia provides known Mtb NadE inhibitor scaffolds (Wang series) and disease biology expertise; Chemify designs and synthesises improved analogues via the Chemputation platform.

Strategic tierFoundational Academic Partner (Spin-Out Origin)TypeOthers
Description

Chemify was founded in 2022 as a spin-out from the University of Glasgow, building on 20+ years of research from the Cronin Group led by founder and CEO Professor Lee Cronin (Regius Chair of Chemistry). The company's registered office is at the School of Chemistry, University of Glasgow, G12 8QQ.

Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

AI-driven drug discovery company using automated design-synthesis-test cycles to develop small-molecule therapeutics for pharma partners. Operates a similar partnership-based business model with upfront, milestone, and royalty economics, directly competing with Chemify for enterprise pharma AI chemistry engagements.

TypeBroad incumbent
Description

AI-driven drug discovery platform combining high-throughput wet-lab automation with machine learning across multiple therapeutic areas. Larger and publicly listed, Recursion competes with Chemify for pharma AI partnerships but operates a much broader biology-first platform rather than chemistry-focused programmable synthesis.

TypeDirect peer
Description

Machine-learning-driven drug discovery company combining automated wet-lab experimentation with predictive models for small-molecule and target discovery. Targets similar pharma partnership economics and operates at the intersection of AI and laboratory automation, comparable to Chemify's design-make-test-analyze positioning.

TypeBroad incumbent
Description

Computational chemistry platform providing physics-based molecular simulation and predictive modeling for drug discovery and materials science. Overlaps with Chemify on AI-driven molecular design and route planning but is a broader, more established software-first incumbent without the physical robotic synthesis layer.

5Iambic Therapeutics
TypeDirect peer
Description

AI-driven drug discovery company combining machine learning models with automated chemistry to design and synthesize novel small molecules. Directly comparable to Chemify in using AI-generated designs executed through automated synthesis, and competes for similar pharma partnership deals.

6Isomorphic Labs
TypeBroad incumbent
Description

Alphabet-owned drug discovery company spun out of DeepMind, applying AI to molecular design and protein structure prediction. A well-capitalized broad incumbent in AI drug discovery whose strategy intersects with Chemify's generative chemistry ambitions, though without an equivalent physical synthesis automation layer.

TypeDirect peer
Description

AI-enabled drug discovery platform combining patient data, molecular dynamics, and automated chemistry to develop small-molecule therapeutics. Uses a similar partnership-driven model with pharma and operates at the AI-chemistry intersection that Chemify targets.

TypeEmerging player
Description

Generative AI company focused on protein and biologics design rather than small molecules. An emerging player in the broader AI-driven bio-design space with partial overlap to Chemify's generative design ambitions but a different molecular modality.

TypeEmerging player
Description

Remote, automated wet-lab facility that allows scientists to run experiments through software interfaces. Shares Chemify's philosophy of fully automated lab execution but focuses on general life-science experimentation rather than small-molecule synthesis programming.

TypeOthers
Description

Cloud-based R&D informatics platform widely adopted by biotech and pharma for experiment tracking, molecular biology, and chemistry data management. Not a direct competitor but an adjacent enabling technology ecosystem participant that Chemify customers may already use for laboratory data infrastructure.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles16 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors17 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Chemify

Digital Chemistry Platformchemify.io

Chemify is a Glasgow-based digital chemistry company that uses its Chemputation platform — combining generative AI design, ML-based route optimization, the proprietary χDL chemical programming language, and automated robotic synthesis — to design and produce small molecules for pharma, biotech, advanced-materials, and global-health partners under bespoke R&D and milestone/royalty agreements.

What Chemify does

Chemify is a privately held digital chemistry company founded in 2022 as a spin-out from the University of Glasgow, headquartered in Glasgow with an operational footprint extending to the United States (planned Silicon Valley hub) and Japan (via Zeon partnership). The company operates the Chemputation platform, which integrates a generative AI design engine (Quantum Chemputation), an ML-based route optimization tool (ASSEMBLER), and a proprietary universal chemical programming language (χDL) with advanced robotic synthesis infrastructure housed in the Maryhill Chemifarm facility opened in 2025. Together these components execute closed-loop Design-Make-Test-Analyze cycles that translate target molecules into executable, hardware-agnostic chemical code, with the platform reporting a 10x reduction in time from conception to compound synthesis.

Chemify generates revenue primarily through bespoke, multi-year R&D and custom-synthesis collaborations with pharmaceutical, biotechnology, advanced-materials and global-health counterparties, complemented by success-based clinical and regulatory milestones and tiered royalties on compounds the platform designs. Pricing is quote-based and negotiated per program, with disclosed deal economics such as USD $30M+ in payments plus single-digit royalties per molecule in the Prepaire Labs opioid program. Its go-to-market is enterprise sales-led (CBO and SVP Business Development) supplemented by industry conferences, scientific thought leadership, and PR-driven awareness. The company has raised over $90M across a $43M Series A (Aug 2023) and an oversubscribed $50M+ Series B (Oct 2025), with a strategic investment from Zeon Ventures in February 2026 and grant funding from the Bill & Melinda Gates Foundation totaling approximately £2.4M for tuberculosis and malaria drug discovery.

Chemify firmographics

Firmographics
Name
Chemify
Legal name
Chemify Limited
Website
https://chemify.io
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
101–250 employees
Short description
Chemify is a Glasgow-based digital chemistry company that uses its Chemputation platform — combining generative AI design, ML-based route optimization, the proprietary χDL chemical programming language, and automated robotic synthesis — to design and produce small molecules for pharma, biotech, advanced-materials, and global-health partners under bespoke R&D and milestone/royalty agreements.
Ownership category
akta.pro rank

Chemify industry classification

Industry
Product category
Digital Chemistry Platform
NAICS
Pharmaceutical and Medicine Manufacturing (32541)
SIC
Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAGAJAE
Cheminformatics & Molecular Modeling / CADD
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • Digital chemistry platform
  • Automated drug discovery
  • Chemical programming language
  • Robotic synthesis services
  • AI molecular design

Where Chemify is headquartered

Location

Headquarters

HQ city
Glasgow
HQ country
United Kingdom
HQ region
Europe

Offices3 records

Markets served

Chemify business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Bespoke R&D Partnerships / Custom Synthesis: Project-based collaborations with pharmaceutical, biotechnology, and materials companies in which Chemify designs, discovers, and synthesises bespoke molecules using the Chemputation platform. Engagements span multiple years and milestones, often including a defined number of design–make cycles or compounds delivered.
  2. Success-Based Milestones and Royalties: Multi-year milestone and royalty structures tied to clinical and regulatory progress of compounds Chemify designs for partners. For example, the Prepaire Labs opioid program includes at least USD $30 million in payments and pre-negotiated clinical/regulatory milestones per developed molecule, plus single-digit royalties on resulting products. Similar tiered royalty structures apply to Dewpoint Therapeutics.
  3. Option-to-Acquire Compound Rights: For certain partnerships (e.g., Dewpoint), the partner may exercise an option to acquire compounds designed by Chemify; in exchange Chemify receives pre-negotiated, success-driven payments and tiered royalties based on clinical and regulatory milestones.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractQuote-based bespoke partnership engagements initiated via the 'Partner With Us' form.

Go-to-market motion4 records

Distribution channels5 records

Marketing channels6 records

Chemify product offering

Product offering

Core offering

Chemify provides an integrated digital chemistry platform, called Chemputation, that combines ML-based molecular design (Quantum Chemputation), ML-driven route optimization (ASSEMBLER), and a proprietary universal chemical programming language (χDL) executed by advanced robotic synthesis systems. Through its Chemifarm automated synthesis facility in Glasgow, the company delivers fully automated Design–Make–Test–Analyze cycles to pharmaceutical, biotechnology, advanced materials, and global health customers under bespoke R&D partnerships and milestone/royalty-bearing collaboration agreements. Chemify also offers standalone capabilities including upfront Chemputability makeability assessment and massive library derivatization deep into chemical space.

Product overview

Chemify offers a single unified platform called "Chemputation" that combines three interlocking technology modules — Quantum Chemputation (generative AI-driven molecular design), ASSEMBLER (ML-based route optimization using the proprietary reaction database), and χDL (the world's first universal chemical programming language) — executed by Chemify's advanced robotics infrastructure within the Chemifarm automated synthesis facility in Maryhill, Glasgow. The platform is delivered to partners as a digital-to-physical discovery service spanning custom synthesis, scale-up for preclinical testing, Chemputability makeability scoring, and massive library derivatization deep into chemical space. Together these modules enable fully automated Design-Make-Test-Analyze cycles that translate target molecules into executable chemical code run on robotic systems.

Differentiator

Problem solved

Functional benefit

Brands

  • Chemifarm: Chemify's branded fully automated synthesis facility (Chemputation facility); the first Chemifarm opened in Maryhill, Glasgow in 2025.
  • Chemputation
  • χDL (ChiDL)
  • ASSEMBLER

Products and services

  • Chemputation Technology Platform Integrated digital chemistry platform combining Quantum Chemputation (ML-based generative molecular design), ASSEMBLER (route optimization), and χDL (universal chemical programming language), executed by advanced robotic systems to deliver fully automated Design-Make-Test-Analyze cycles for pharmaceutical, biotechnology, materials, and global health partners.
  • Chemputability Makeability Assessment Algorithmically scores each molecule's Chemputability (practical makeability) before synthesis by comparing reaction steps against Chemify's database of tens of thousands of validated, optimized, and automated reactions; suggests Chemputable alternative structures when designs are not readily synthesizable.
  • Massive Library Derivatization Generates large derivatized libraries from established synthetic routes encoded in χDL, incorporating physicochemical parameters, druglike parameters, and makeability considerations; enables deep chemical-space exploration and gram-scale automated synthesis from a key advanced intermediate.

Quantifiable outcome

  • 10x reduction in time from initial conception to compound synthesis via Chemputation platform
  • +2 more outcomes

Companies that use Chemify

Customer profile

Named customers6 records

Segments4 records

Ideal customer profiles3 records

Chemify technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature7 records

Chemify partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered flagship co-development partner for cardiometabolic pipeline, flagship strategic partner for opioid programs, flagship strategic partner for oncology and neurodegeneration, core co-development partner for tb program and foundational academic partner (spin-out origin).

  • Sanacorflagship co-development partner for cardiometabolic pipelineStrategic or Co-development Partner · 25 February 2026Collaboration announced February 2026 to discover and develop orally available small-molecule inhibitors targeting mitochondrial dysfunction in cardiometabolic diseases, with initial focus on diabetic cardiovascular disease. Combines Chemify's ML-based Chemputation platform for molecular design and automated synthesis with Sanacor's translational biology platform led by CEO and Co-founder Dr. Michael Widlansky.
  • Prepaire Labsflagship strategic partner for opioid programsStrategic or Co-development Partner · 18 January 2024Expanded partnership announced January 2024 with the 'Toxifree' program to develop a novel class of digitally discovered non-addictive opioids and addiction treatments in response to FDA's CDER guidance on stimulant use disorder. Combines Chemify's Chemputation platform with Prepaire's open-architecture drug discovery platform. Chemify entitled to at least USD $30 million in payments and pre-negotiated clinical/regulatory milestones per developed molecule, plus single-digit royalties.
  • Dewpoint Therapeuticsflagship strategic partner for oncology and neurodegenerationStrategic or Co-development Partner · 12 September 2023Partnership announced September 2023 to design, discover, and automatically synthesize novel molecules against condensate targets in Dewpoint's oncology and neurodegeneration pipeline. Combines Chemify's chemistry AI and automation platform with Dewpoint's condensate biology platform. Chemify receives pre-negotiated success-driven payments and tiered royalties; Dewpoint may exercise an option to acquire compounds.
  • Lgeniacore co-development partner for tb programStrategic or Co-development PartnerCollaborating with Chemify on the Bill & Melinda Gates Foundation–funded tuberculosis drug discovery program. Lgenia provides known Mtb NadE inhibitor scaffolds (Wang series) and disease biology expertise; Chemify designs and synthesises improved analogues via the Chemputation platform.
  • University of Glasgowfoundational academic partner (spin-out origin)OthersChemify was founded in 2022 as a spin-out from the University of Glasgow, building on 20+ years of research from the Cronin Group led by founder and CEO Professor Lee Cronin (Regius Chair of Chemistry). The company's registered office is at the School of Chemistry, University of Glasgow, G12 8QQ.

Scale indicators8 records

Recent moves10 records

Expansion highlights5 records

Chemify competitors and assessment

Company assessment

Direct peers

  • Exscientia: AI-driven drug discovery company using automated design-synthesis-test cycles to develop small-molecule therapeutics for pharma partners. Operates a similar partnership-based business model with upfront, milestone, and royalty economics, directly competing with Chemify for enterprise pharma AI chemistry engagements.
  • Insitro: Machine-learning-driven drug discovery company combining automated wet-lab experimentation with predictive models for small-molecule and target discovery. Targets similar pharma partnership economics and operates at the intersection of AI and laboratory automation, comparable to Chemify's design-make-test-analyze positioning.
  • Iambic Therapeutics: AI-driven drug discovery company combining machine learning models with automated chemistry to design and synthesize novel small molecules. Directly comparable to Chemify in using AI-generated designs executed through automated synthesis, and competes for similar pharma partnership deals.
  • Valo Health: AI-enabled drug discovery platform combining patient data, molecular dynamics, and automated chemistry to develop small-molecule therapeutics. Uses a similar partnership-driven model with pharma and operates at the AI-chemistry intersection that Chemify targets.

Broad incumbents

  • Recursion Pharmaceuticals: AI-driven drug discovery platform combining high-throughput wet-lab automation with machine learning across multiple therapeutic areas. Larger and publicly listed, Recursion competes with Chemify for pharma AI partnerships but operates a much broader biology-first platform rather than chemistry-focused programmable synthesis.
  • Schrödinger: Computational chemistry platform providing physics-based molecular simulation and predictive modeling for drug discovery and materials science. Overlaps with Chemify on AI-driven molecular design and route planning but is a broader, more established software-first incumbent without the physical robotic synthesis layer.
  • Isomorphic Labs: Alphabet-owned drug discovery company spun out of DeepMind, applying AI to molecular design and protein structure prediction. A well-capitalized broad incumbent in AI drug discovery whose strategy intersects with Chemify's generative chemistry ambitions, though without an equivalent physical synthesis automation layer.

Emerging players

  • Cradle Bio: Generative AI company focused on protein and biologics design rather than small molecules. An emerging player in the broader AI-driven bio-design space with partial overlap to Chemify's generative design ambitions but a different molecular modality.
  • Emerald Cloud Lab: Remote, automated wet-lab facility that allows scientists to run experiments through software interfaces. Shares Chemify's philosophy of fully automated lab execution but focuses on general life-science experimentation rather than small-molecule synthesis programming.

Others

  • Benchling: Cloud-based R&D informatics platform widely adopted by biotech and pharma for experiment tracking, molecular biology, and chemistry data management. Not a direct competitor but an adjacent enabling technology ecosystem participant that Chemify customers may already use for laboratory data infrastructure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Chemify social profiles

Digital presence

Chemify financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Chemify leadership team

Management profile

Number of profiles

Profiles16 records

Chemify funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors17 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Chemify M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Chemify

What does Chemify do?

Chemify provides an integrated digital chemistry platform, called Chemputation, that combines ML-based molecular design (Quantum Chemputation), ML-driven route optimization (ASSEMBLER), and a proprietary universal chemical programming language (χDL) executed by advanced robotic synthesis systems. Through its Chemifarm automated synthesis facility in Glasgow, the company delivers fully automated Design–Make–Test–Analyze cycles to pharmaceutical, biotechnology, advanced materials, and global health customers under bespoke R&D partnerships and milestone/royalty-bearing collaboration agreements. Chemify also offers standalone capabilities including upfront Chemputability makeability assessment and massive library derivatization deep into chemical space.

Is Chemify a public or private company?

Chemify is a private company. It is classified as venture growth investor backed and is currently operating.

When was Chemify founded?

Chemify was founded in 2022. It employs 101 to 250 people.

Where is Chemify based?

Chemify is headquartered in Glasgow, United Kingdom, in the Europe region.

How does Chemify make money?

Three revenue lines are on record. Bespoke R&D Partnerships / Custom Synthesis are the primary driver. The others are success-Based Milestones and Royalties and option-to-Acquire Compound Rights.

Who are Chemify's main competitors?

Direct peers on record are Exscientia, Insitro, Iambic Therapeutics and Valo Health. Broad incumbents are Recursion Pharmaceuticals, Schrödinger and Isomorphic Labs. Emerging players are Cradle Bio and Emerald Cloud Lab. Benchling is listed as an others.

Does Chemify have an API?

No public API is recorded for Chemify.

What industry is Chemify in?

Chemify's product category is Digital Chemistry Platform. Its primary akta.pro industry code is HLAGAJAE, Cheminformatics & Molecular Modeling / CADD, with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 32541 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business PageChemify Appoints Rima Alameddine to Its Board of DirectorsChemify appointed Rima Alameddine as independent non-executive director, bringing three decades of experience from Cisco, NVIDIA, and IonQ. The appointment follows an £89.9 million expansion and a Series B round extended to £51.9 million, bringing total funding to over £110 million.FinSMEsChemify Raises £22M in GrantsChemify, a Glasgow-based AI and robotics chemical discovery platform, received £22M in grants from Scottish Enterprise and the UK Government. The funding brings total funding to £110M, which the company will use to expand operations, advance its Chemify Genesis system, and grow its workforce.StartupmagChemify secures £22m grant from Scottish Enterprise and UK GovernmentChemify, a Glasgow biotech startup, secured £22m in grant funding from Scottish Enterprise and the UK Government to expand its automated chemistry facilities and scale its Chemify Genesis discovery platform. The grant, comprising £16m and £6m, extends its Series B to £51.9m, bringing total capital to about £110m. The funding will support building a next-generation Chemifarm and growing its Scottish workforce from 152 to roughly 450.Unite.AIChemify Secures £22M to Scale AI-Powered Chemistry and Build Its Next ChemifarmChemify secured £22 million in grants and expanded its Series B to £51.9 million, bringing total funding to over £110 million. The funds will build a second Chemifarm and extend Chemify Genesis, aiming to double Chemputation capacity. The company plans to grow its Scottish workforce from 152 to 450.FinancialContent Business PageChemify Becomes the First Chemistry Hyperscaler with £22 Million in Grants from Scottish Enterprise and the UK GovernmentChemify received £22 million in grants from Scottish Enterprise and the UK Government to expand its digital chemistry capacity. The funding, plus a Series B extension, brings total funding to over £110 million and will grow its Scottish workforce from 152 to about 450. The company plans additional Chemifarms in other countries.Business Wire BlogChemify Becomes the First Chemistry Hyperscaler with £22 Million in Grants from Scottish Enterprise and the UK GovernmentChemify received £22 million in grants from Scottish Enterprise and the UK Government to expand its digital chemistry capacity. The funding will double its Chemifarm capacity and increase its workforce from 152 to about 450 over three years, bringing total funding to over £110 million.CityAMLocal growth is not a zero-sum gameResearch from the Growing Together Alliance and Brunel Centre shows UK innovation clusters are connected, with venture capital flows and company movements across regions. Since 2016, Ox-Cam VC has invested at least £154m in UK businesses outside the corridor, and half of Innovate UK projects with Ox-Cam partners involve external companies. Policymakers should target support for clusters in the Northern Corridor, Ox-Cam, and London.National TodayChemify and Sanacor Collaborate to Discover and Develop Small Molecule Therapies for Cardiometabolic DiseasesChemify and Sanacor announced a collaboration on February 25, 2026, to discover and develop small molecule therapies targeting mitochondrial dysfunction in cardiometabolic diseases, with an initial focus on diabetic cardiovascular disease. The partnership combines Chemify's AI-powered Chemputation technology for molecular design and automated synthesis with Sanacor's research on dysregulated mitochondrial dynamics and vascular dysfunction in type 2 diabetes models. The collaboration aims to address a major unmet medical need, as there are currently no approved therapies that directly address the underlying vascular dysfunction in diabetic cardiovascular disease.PharmiWeb.comChemify and Sanacor Collaborate to Discover and Develop Small Molecule Therapies for Cardiometabolic DiseasesChemify and Sanacor announced a collaboration to discover and develop orally available small-molecule inhibitors targeting mitochondrial dysfunction in cardiometabolic diseases, with an initial focus on diabetic cardiovascular disease. The partnership combines Chemify's ML-based Chemputation technology for molecular design and automated synthesis with Sanacor's translational biology platform, led by CEO and Co-founder Dr. Michael Widlansky. Diabetic cardiovascular disease is a leading cause of mortality among diabetic patients, and no approved disease-modifying therapies currently address its underlying pathophysiology.Insight PartnersHow Chemify digitizes the process of making moleculesChemify, a Glasgow-based startup founded in 2019 and spun out from the University of Glasgow in March 2022, has developed χDL, a proprietary programming language that translates molecular designs into executable code for robotic synthesis of physical chemicals. The company raised a $50M Series B co-led by Insight Partners in October 2025, launched its first fully automated Chemifarm synthesis facility in Glasgow, and received a $1.6M grant in December 2025 for tuberculosis and malaria drug discovery.